Systematic review: drug repositioning for congenital disorders of glycosylation (CDG)

S Brasil, M Allocca, SCM Magrinho, I Santos… - International Journal of …, 2022 - mdpi.com
Advances in research have boosted therapy development for congenital disorders of
glycosylation (CDG), a group of rare genetic disorders affecting protein and lipid …

A decision-making approach for determining strategic priority of sustainable smart city services from citizens' perspective: A case study of Hong Kong

Y Liu, T Ji, HC Ho, C Guo, HH Wei - Sustainable Cities and Society, 2024 - Elsevier
The development of sustainable smart city (SC) services is often carried out with limited
resources, but there is little discussion about the strategic priority of promoting SC …

Embedding patient-centricity by collaborating with patients to transform the rare disease ecosystem

R Sharma, S Ahmed, J Campagnari, W Huff… - Pharmaceutical …, 2023 - Springer
What is patient-centricity? In some contexts, it has been associated with targeting therapies
based on biomarkers or enabling healthcare access. There has been a surge in patient …

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health …

C Pascoal, I Ferreira, C Teixeira, E Almeida… - Orphanet Journal of …, 2022 - Springer
Background Congenital disorders of glycosylation (CDG) are a growing group of rare
genetic disorders. The most common CDG is phosphomannomutase 2 (PMM2)-CDG which …

Semne neurologice evocatoare în tulburările congenitale ale glicozilării.

D Blăniţă, C Boiciuc, S Hadjiu… - Journal for Neurology & …, 2022 - search.ebscohost.com
SUMMARY Congenital Disorders of Glycosylation (CDG) are a group of metabolic errors
caused by pathogenic variants in genes encoding proteins involved in the glycosylation …